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Abstract
Objective: The hexosamine biosynthesis pathway (HBP) flux and protein O-linked N-acetyl-glucosamine (O-GlcNAc) levels
have been implicated in mediating the adverse effects of diabetes in the cardiovascular system. Activation of these
pathways with glucosamine has been shown to mimic some of the diabetes-induced functional and structural changes in
the heart; however, the effect on cardiac metabolism is not known. Therefore, the primary goal of this study was to
determine the effects of glucosamine on cardiac substrate utilization.
Methods: Isolated rat hearts were perfused with glucosamine (0–10 mM) to increase HBP flux under normoxic conditions.
Metabolic fluxes were determined by
13C-NMR isotopomer analysis; UDP-GlcNAc a precursor of O-GlcNAc synthesis was
assessed by HPLC and immunoblot analysis was used to determine O-GlcNAc levels, phospho- and total levels of AMPK and
ACC, and membrane levels of FAT/CD36.
Results: Glucosamine caused a dose dependent increase in both UDP-GlcNAc and O-GlcNAc levels, which was associated
with a significant increase in palmitate oxidation with a concomitant decrease in lactate and pyruvate oxidation. There was
no effect of glucosamine on AMPK or ACC phosphorylation; however, membrane levels of the fatty acid transport protein
FAT/CD36 were increased and preliminary studies suggest that FAT/CD36 is a potential target for O-GlcNAcylation.
Conclusion/Interpretation: These data demonstrate that acute modulation of HBP and protein O-GlcNAcylation in the heart
stimulates fatty acid oxidation, possibly by increasing plasma membrane levels of FAT/CD36, raising the intriguing
possibility that the HBP and O-GlcNAc turnover represent a novel, glucose dependent mechanism for regulating cardiac
metabolism.
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Introduction
Cardiovascular complications, including diabetic cardiomyopa-
thy are the leading cause of excessive premature morbidity and
mortality in diabetic patients. Maladaptive alterations of cardiac
metabolism plays a pivotal role in the development of diabetic
cardiomyopathy [1] and abnormal regulation of carbohydrate and
fatty acid metabolism has been well-characterized as one of the
earliest adverse manifestation of diabetes on cardiac myocyte
function [1,2]. Typically the metabolic shift towards decreased
myocardial carbohydrate oxidation and increased fatty acid
metabolism that occurs in diabetes is attributed to an increase in
circulating lipids via the classical Randle Cycle [3]; however,
hearts from young db/db mice exhibited significantly increased
fatty acid oxidation and decreased carbohydrate oxidation, prior
to the onset of overt hyperglycemia and in the absence of increased
circulating lipids [4]. This suggests that metabolic dysfunction
occurs prior to the onset of overt diabetes and may be due to
mechanisms independent of Randle Cycle.
The modification of proteins by O-linked N-acetylglucosamine
(O-GlcNAc) was first identified by Torres and Hart in 1984 [5]
and there is a growing evidence implicating excessive O-
GlcNAcylation in glucose toxicity and insulin resistance [6,7],
major hallmarks of diabetes mellitus and diabetes-related
complications. In contrast to classical protein glycosylation in
the ER and Golgi, characterized by stable and complex elongated
oligosaccharide structures, O-GlcNAcylation is a dynamic
process involving the reversible addition of a single O-GlcNAc
moiety to serine and threonine residues of nuclear and cytosolic
proteins [8]. This process is regulated by the activities of two key
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attachment of O-GlcNAc and N-acetylglucosaminidase (O-
GlcNAcase), which catalyzes its removal [8]. The activity of
OGT is sensitive to the intracellular concentration of its substrate
[8], UDP-GlcNAc, which is the product of the hexosamine
biosynthesis pathway (HBP). Flux through the HBP and thus the
synthesis of UDP-GlcNAc is regulated in large part by the
metabolism of glucose; this is regulated by L-glutamine-D-fructose
6-phosphate amidotransferase (GFAT), which converts fructose-
6-phosphate to glucosamine-6-phosphate with glutamine as the
amine donor [9].
Given the central role of glucose in regulating HBP flux and
thus cellular levels of O-GlcNAc, accumulating evidence suggests
that increased protein O-GlcNAcylation due to nutrient excess
mediate the adverse effects of diabetes in the cardiovascular
system. While much of the work in this area has focused on
endothelial-vascular complications [10,11,12], increased O-
GlcNAc levels have been linked to cardiac myocyte dysfunction
seen in diabetes [13,14], as well as implicated in impaired
hypertrophic and alpha-adrenergic signaling [15,16]. An early
consequence of diabetes on the heart is an increased fatty acid
oxidation, which has been implicated in diabetes-induced cardiac
dysfunction [17,18]. As noted above, the increase in myocardial
fatty acid utilization seen in diabetes has typically been attributed
to an increase in circulating lipids and implicated in lipotoxicity,
mitochondrial dysfunction and impaired myocardial bioenergetics
[1,2,17,18]. However, Luo et al. reported that an increase in O-
GlcNAc levels in adipocytes by the activation of the HBP with
glucosamine, increased fatty acid oxidation [19], which raises the
intriguing possibility that that the HBP and protein O-GlcNAcyla-
tion could modulate regulation of substrate metabolism in the
heart.
Although it has been shown that acute increases in HBP flux
and O-GlcNAc with glucosamine mimicked some of the effects of
diabetes on the heart [14,20], there are no data regarding the role
of the HBP and O-GlcNAc in the regulation of cardiac
metabolism. Therefore, the goal of this study was to determine
the effects of activation of the HBP with glucosamine on cardiac
metabolic regulation. We found that glucosamine significantly
decreased total carbohydrate oxidation, increased fatty acid
oxidation, and this was associated with increased cardiac O-
GlcNAcylation. In addition we found that this increase in fatty
acid oxidation appeared to be a consequence of increased levels of
the fatty acid transporter FAT/CD36 at the plasma membrane
rather than alterations in AMPK or ACC activity. Preliminary
studies also indicate that FAT/CD36 may be subject to direct O-
GlcNAc modification.
Materials and Methods
Ethics statement
Animal experiments were approved by the University of
Alabama Institutional Animal Care and Use Committee (UAB
APN 100408442) and conformed to the Guide for the Care and
Usage of Laboratory Animals published by the National Institutes
of Health (NIH Publication No. 85-23, 1996).
Materials
Non-fasted, 300–350 g male Sprague Dawley rats (Charles
Rivers Laboratories) were used in all studies. Unless otherwise
noted, chemicals were obtained from Fisher Scientific (Santa
Clara, CA) or Sigma-Aldrich (St. Louis, MO). Essentially fatty acid
free bovine serum albumin was obtained from Serologicals
Proteins Inc. (Kankakee, IL).
13C-labeled substrates were obtained
from Cambridge Isotope Laboratories (Andover, MA).
Isolated heart perfusions
Animals were anesthetized, hearts rapidly excised and perfused
retrogradely at a constant perfusion pressure of 75 mmHg with
Krebs-Henseleit buffer containing (in mM) glucose 5.0, lactate 1.0,
pyruvate 0.1, palmitate 0.32, glutamine 0.5 and 3% BSA (fatty
acid free) plus 50 mU/mL insulin (NovoNordisk), as previously
described [21]. Cardiac function was monitored via a fluid-filled
balloon placed into the left ventricle and end-diastolic pressure
(EDP) was set to 5 mmHg. All hearts were paced continuously at
320 beats/min.
Hearts were assigned to one of six groups and perfused for
60 minutes under normoxic conditions with perfusion buffer
containing: 1) 0 mM glucosamine (n=8); 2) 0.05 mM glucosamine
(n=5); 3) 0.1 mM glucosamine (n=8); 4) 1.0 mM glucosamine
(n=4); 5) 5.0 mM glucosamine (n=8); and 6) 10.0 mM glucos-
amine (n=7).
The upper concentrations of glucosamine were chosen based on
our earlier report demonstrating that perfusion of normal hearts
with 5 mM glucosamine mimicked the effects of short-term
diabetes on the heart [22] and the study by Luo et al. [19], who
reported that 10 mM glucosamine increased fatty acid oxidation
in cultured adipocytes. To determine the range of glucosamine
concentrations, which modulated fatty acid oxidation, additional
experiments were performed at 0.05, 0.1 and 1 mM.
13C-isotopomer analyses
Hearts were perfused with [U-
13C]palmitate, [3-
13C]lactate and
[2-
13C]pyruvate for the final 40 minutes of the protocol at which
time hearts were freeze-clamped, acid extracted and
13C-NMR
isotopomer analysis was performed as previously described
[23,24]. This enabled us to determine the fraction of total
acetyl-CoA entering the TCA cycle that originating from
unlabeled, [1,2-
13C]-, [2-
13C]- and [1-
13C]acetyl-CoA originating
from unlabeled glucose, [U-
13C]-palmitate, [3-
13C]-lactate and
[2-
13C]-pyruvate respectively [23,24]. We have previously shown
that under these perfusion conditions in the isolated rat heart,
there is negligible contribution from endogenous triglycerides to
unlabeled acetyl-CoA formation [25].
Determination of lactate efflux and uptake rates
1H-NMR spectroscopy was used to determine the ratio of
unlabeled lactate formed by the exogenous glucose or endogenous
glycogen and [3-
13C]lactate added to the perfusate. These data,
multiplied by the total lactate concentration in the effluent and
coronary flow, were used to determine the rates of exogenous
[3-
13C]lactate uptake and unlabeled endogenously produced
lactate efflux as described in detail elsewhere [23,24].
Immunoblot analyses
Tissue was homogenized in the appropriate lysis buffer as
previously described for O-GlcNAc [20,21], and for phospho- and
total-ACC and phospho- and total-AMPK [26]. Whole heart
lysates were separated on SDS-PAGE and transferred to PVDF
membrane (Pall). Membranes were probed for O-GlcNAc
(CTD110.6 antibody, a kind gift from Mary-Ann Accavitti,
UAB Epitope Recognition and Immunoreagent Core), and for
phospho- and total-ACC (Cell Signaling) and phospho- and total-
AMPK (Cell Signaling) antibodies. Blots were visualized with
enhanced chemiluminescence assay (Pierce) and the signal was
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quantified using Labworks analysis software (UVP).
Membrane associated FAT/CD36 levels
Tissue powder was lyzed in ice-cold homogenization buffer
containing (in mM) Tris (pH: 7.4) 20.0, EDTA 5.0, sucrose 250.0,
phenylmethanesulfonyl fluoride 1.0 and 2.5% protease inhibitor
cocktail. Tissue homogenates were centrifuged at 1,000 g for
10 min. The resulting supernatant was ultracentrifuged at
110,000 g for 75 min at 4uC. The pellet (=particulate membrane
fraction) was resuspended and incubated for 30 min in ice-cold
solubilization buffer containing (in mM) Tris (pH: 7.4) 50.0, NaCl
100.0, LiCl 50.0, EDTA 5.0, and 0.5 (v/v) % Triton X-100, 0.05
(w/v) % SDS, 0.5 (w/v) % sodium deoxycholate, and 0.02 (w/v)
% sodium azide. The samples were centrifuged at 14,000 g for
10 min at 4uC, and the supernatant was mixed with reducing
sample buffer (BioRad) and boiled for 5 min. Proteins were
resolved by SDS-PAGE and blotted on Immobilion-P PVDF
membranes (Millipore). The blots were probed with FAT/CD36
antibody (Cascade Biosciences) and visualized as described above.
GAPDH and pan-cadherin antibodies (Abcam) were used to verify
the purity of the membrane fraction and pan-cadherin was used as
a loading control.
Immunoprecipitation
Cardiac tissue was homogenized to obtain either whole tissue
(w) or membrane fraction (m) lysates, as described above. Samples
containing equal amount of protein (1000 mg) were mixed with
5 mg of polyclonal rabbit anti-CD36 antibody (sc-9154, Santa
Cruz Biotechnology) overnight at 4uC with protein A agarose
beads (Upstate). The agarose beads then were washed three times
in PBS containing 1% NP-40 followed by washes with PBS for
three times. Antigens were eluted from the beads and boiled for
5 min in Laemmli buffer prior to SDS-PAGE. Immunoblots were
incubated with CTD 110.6 (1:1000), anti-CD36 (1:500), and anti-
OGT (DM-17; 1:1000, Sigma) antibodies for overnight at 4uC,
followed by incubation with appropriate secondary antibodies and
chemiluminescence visualization.
Control experiments included immunoprecipitation in the
absence of samples and/or antibody. The CD36 positive protein
band at the appropriate molecular weight (,88 kD) was only
observed in the presence of both antibody and sample (data not
shown), demonstrating that this band was indeed CD36 and not a
non-specific protein band. The specificity of the O-GlcNAc
antibody was also confirmed by co-incubation with 10 mM N-
acetylglucosamine [27].
HPLC analyses
Approximately 50 mg of frozen tissue powder was homogenized
in 1 mL ice-cold 0.3 mol/L perchloric acid and centrifuged at
15,000 g for 15 min at 4uC. PCA was removed from the
supernatant with 2 volumes of 1:4 trioctylamine:1,1,2-trichloro-
trifluoroethan mixture. Samples were loaded on Partisil 10 SAX
column (Beckman), nucleotide sugars were measured at 262 nm
using 2 mL/min flow rate and linear salt and pH gradient from
5 mM to 750 mM (NH4)H2PO4 and from pH 2.8 to 3.7 [21].
Data analysis
Data are presented as means 6 standard errors. Differences
between experimental groups were evaluated with one-way
ANOVA with Dunnett’s posthoc test or Student’s t-test as
indicated in the figure legends. Statistically significant differences
between groups were defined as P,0.05 and are indicated in the
legends of figures.
Results
Effect of glucosamine on cardiac function
Consistent with earlier studies [21,28], perfusion of the hearts
with 0.05, 0.1, 1.0, 5.0 or 10.0 mM glucosamine for 60 minutes
had no effect on rate pressure product, 6dp/dt or coronary flow
compared to the control hearts, perfused without glucosamine
(Table 1).
UDP-GlcNAc and O-GlcNAc levels
Protein O-GlcNAc levels assessed by immunoblot analysis
indicated a clear dose response with glucosamine (Figures 1A, B).
Perfusion for 60 min with as little as 0.05 mM glucosamine
resulted in ,40% increase in O-GlcNAc levels and a maximal 2-
fold increase in O-GlcNAc was seen with 5 mM glucosamine
(Figures 1A, B). Sypro staining was used to ensure equal protein
loading for the O-GlcNAc immunoblots; overall O-GlcNAc levels
were assessed by densitometric analyses and normalized to
untreated control group. Note that Figure 1A is a representative
image, with 2 samples for each concentration, whereas the mean
data in Fig. 1B is from an n of 3–9 for each concentration as
indicated in the figure legend.
UDP-GlcNAc levels exhibited similar response to glucosamine
perfusions as O-GlcNAc levels; there was a significant increase
with 0.05 mM glucosamine and a maximal ,2-fold increase with
1 mM (Figure 1C). Others have reported that in cell culture
studies glucosamine treatment was associated with decreased ATP
levels [29]; however, here in the isolated perfused heart we found
that there was no effect of glucosamine on ATP (Figure 1D).
Table 1. Cardiac function of isolated rat hearts perfused with 0 (n=8), 0.05 (n=5), 0.1 (n=10), 1 (n=4), 5 (n=8) and 10 mM (n=7)
glucosamine for 60 minutes (hearts were paced at 320 beats/min rate).
Glucosamine concentration (mM)
0 0.05 0.1 1 5 10
RPP (mmHg/min610
23) 29.161.0 33.262.3 28.061.1 29.862.4 28.761.5 31.161.3
+dp/dt (mmHg/s610
23) 4.160.2 4.160.3 3.560.1 4.060.4 3.660.2 a3.660.2
2dp/dt (mmHg/s610
23) 2.160.1 2.260.2 1.860.1 2.060.2 1.960.1 2.160.3
Coronary flow (ml/min) 11.560.8 12.260.6 11.160.4 11.560.7 12.560.6 13.560.9
Glucosamine had no effect either on cardiac or on coronary flow. (RPP: rate pressure product=left ventricular developed pressure6heart rate; dp/dt: change of pressure
over time).
doi:10.1371/journal.pone.0018417.t001
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Hearts were perfused with [U-
13C]palmitate, [3-
13C]lactate,
[2-
13C]pyruvate and unlabeled glucose; under the conditions of
these experiments there is negligible contribution from endoge-
nous triglycerides to unlabeled acetyl-CoA formation [25].
Therefore, the relative contribution of glucose to total substrate
entry into the TCA cycle is determined from the fraction of
unlabeled acetyl-CoA. Since glucosamine was not enriched with
carbon-13, any metabolism of glucosamine via glycolysis would be
reflected in an increase in glucose oxidation or glycolysis.
However, glucosamine had no effect on the relative contribution
of glucose to overall substrate oxidation (Fig. 2A) or the rate of
unlabeled glycolytic lactate efflux (Figure 3A). Surprisingly,
however, glucosamine significantly decreased both pyruvate and
lactate oxidation (Figures 2B, C) and this was associated with a
concomitant increase in palmitate oxidation (Figure 2D). The
effect of glucosamine on lactate and palmitate oxidation was
apparent with as little as 0.05 mM glucosamine and was maximal
at 0.1 mM. Consistent with the ,2-fold decrease in lactate
oxidation, glucosamine decreased exogenous
13C-labeled lactate
uptake rates by ,2-fold (Figure 3B). This is in agreement with
previous studies, showing that the primary metabolic fate of
exogenous lactate uptake was subsequent oxidation [30].
AMPK and ACC phosphorylation
Since glucosamine increased AMPK activity and ACC
phosphorylation in adipocytes [19] we examined the effects of
glucosamine on AMPK and ACC phosphorylation in heart.
AMPK phosphorylation levels were not significantly altered at any
glucosamine concentration (data not shown); since a maximal
effect on fatty acid oxidation was seen with 1 mM glucosamine we
then compared only the untreated control and 0.1 mM glucos-
amine groups (Figure 4A). While phospho-AMPK levels appear to
be modestly elevated in the 0.1 mM group, this was not
statistically significant, although, there was greater variance in
the control group due to one outlier. However excluding this
Figure 1. Effect of glucosamine on A, B) Overall cardiac O-GlcNAc levels; C) UDP-HexNAc concentrations and D) ATP
concentrations.
* P,0.05 vs. 0 mM, one-way ANOVA with Dunnett’s posthoc test. Western blots: 0 mM (n=8), 0.05 mM (n=5), 0.1 mM (n=9),
1 mM (n=4), 5 mM (n=8), 10 mM (n=7). HPLC: 0 mM (n=4), 0.05 mM (n=5), 0.1 mM (n=5), 1 mM (n=4), 5 mM (n=3), 10 mM (n=3). Note that
equal protein loading for the O-GlcNAc immunoblots was assessed by Sypro staining and overall O-GlcNAc levels were normalized to untreated
control group.
doi:10.1371/journal.pone.0018417.g001
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addition to reducing the variance in the control group it also
decreased the differences between the two means. In Fig. 4B we
compared ACC phosphorylation between untreated control and
0.1 mM glucosamine groups; again there is no significant
difference between the two groups. As with AMPK there was
one outlier in the control group; however, excluding this from the
analysis also did not alter the conclusions. While not significant
ACC phosphorylation levels were modestly decreased in the
0.1 mM glucosamine group; interestingly in 5 and 10 mM
glucosamine groups there was a significant ,30% decrease in
phospho-ACC levels (data not shown). While this suggests that
glucosamine may affect ACC phosphorylation, it should be noted
that a lower ACC phosphorylation would typically be associated
with decreased rather than increased fatty acid oxidation as seen
here.
Membrane associated FAT/CD36 levels
Fatty acid transport into the heart is regulated by membrane
levels of FAT/CD36 [31,32]; therefore, we determined the effect
of glucosamine on membrane levels of FAT/CD36. As seen in
Figures 5A, B glucosamine treatment markedly increased FAT/
CD36 levels in the membrane fraction in a concentration
dependent manner; ANOVA indicated that there was a significant
treatment effect of glucosamine.
To determine whether the effect of glucosamine on membrane
levels of FAT/CD36 could be a result of direct O-GlcNAc
modification, FAT/CD36 was immunoprecipitated from both
Figure 2. Effect of glucosamine on A) glucose; B) pyruvate; C) lactate and D) palmitate oxidation.
* P,0.05 vs. 0 mM glucosamine, one-
way ANOVA with Dunnett’s posthoc test. 0 mM (n=6), 0.05 mM (n=4), 0.1 mM (n=5), 5 mM (n=5), 10 mM (n=4).
doi:10.1371/journal.pone.0018417.g002
Figure 3. Effect of 0.1 mM glucosamine on A) unlabeled glycolytic lactate efflux and B) exogenous [3-
13C]lactate uptake
* P,0.05
vs. 0 mM, Student’s t-test. 0 mM (n=4), 0.1 mM (n=5).
doi:10.1371/journal.pone.0018417.g003
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lation is known to be a relatively low abundance modification,
these studies were performed on hearts where overall O-GlcNAc
levels were increased ,3 fold by perfusion with a combination of
glucosamine and O-GlcNAcase inhibition (data not shown). As
shown in Figure 5C, there is evidence of O-GlcNAc modification
of FAT/CD36 in both fractions; however, this is particularly
apparent in the membrane fraction. The lack of signal with the co-
incubation of 10 mM N-acetylglucosamine indicates that the
positive staining is a result specific binding of the O-GlcNAc
antibody [27]. We also found that O-GlcNAc transferase (OGT),
the protein responsible for catalyzing the attachment of O-GlcNAc
to proteins co-immunoprecipitates with FAT/CD36.
Discussion
There is a growing appreciation of the importance of protein O-
GlcNAcylation as a key regulator of numerous biological
processes, including nuclear transport, translation and transcrip-
tion, signal transduction, proteasomal degradation and apoptosis
[8,33,34]. Most of our understanding of the role of O-
GlcNAcylation on cellular function is in the context of chronic
diseases, including diabetes and increased O-GlcNAc levels have
been associated with the adverse effects of hyperglycemia and
diabetes on the heart [7,13,14,35,36]. We show here, that acute
activation of the HBP in the isolated perfused rat heart with
glucosamine significantly decreased total carbohydrate oxidation,
increased fatty acid oxidation, and this was associated with
increased levels of O-GlcNAcylation. We also show that in
contrast to studies in adipocytes [19], this glucosamine-induced
increase in fatty acid oxidation appears to be due to increased
levels of the fatty acid transporter FAT/CD36 at the plasma
membrane rather than alterations in AMPK or ACC activity.
Preliminary studies also indicate that FAT/CD36 may be subject
to direct O-GlcNAc modification.
The primary pathway for glucosamine metabolism is via the
HBP leading to the synthesis of UDP-GlcNAc, which is the
precursor for numerous glycosylation reactions in the ER and
Golgi as well as the attachment of O-GlcNAc to serine and
threonine residues of nuclear and cytoplasmic proteins catalyzed
by OGT [8]. In principle, there are also pathways for glucosamine
metabolism, which could result increased glycolytic flux [37,38];
however, glucosamine had no effect on either glucose oxidation or
glucose-derived lactate efflux, i.e., glycolysis (Figure 3). Thus, in
the heart at least, we found no evidence of metabolism of
glucosamine via glycolysis. In contrast to the lack of effect on
glucose metabolism, we found that glucosamine significantly
increased fatty acid oxidation, with a concomitant decrease in
overall carbohydrate oxidation due to lower lactate and pyruvate
oxidation (Figure 2). Furthermore, the effect of glucosamine on
substrate oxidation was apparent at a glucosamine concentration
as low as 0.05 mM with a maximal response at 0.1 mM, which
was associated with significant increases in both UDP-GlcNAc and
O-GlcNAc levels (Figure 1). These data not only support the
notion that the effect of glucosamine on fatty acid oxidation is
mediated via the HBP and the subsequent increase in O-GlcNAc
levels but also suggest that relatively subtle changes in HBP flux
could play an important regulatory role in cardiac metabolism.
Even though concentrations of glucosamine, up to 10 mM, had
no further effect on fatty acid or carbohydrate oxidation beyond
that seen at 0.1 mM, there was a progressive increase in both
UDP-GlcNAc and O-GlcNAc levels. This is consistent with the
notion that the primary pathway for glucosamine metabolism in
the heart is via the HBP and that over the relatively short time
course of these experiments the principal outcome is an increase in
O-GlcNAc levels. It is also worth noting that in contrast to
previous studies, which indicated that high doses of glucosamine
causes a decrease in ATP levels [29], we found that glucosamine
had no effect on ATP levels at any concentration (Figure 1D).
Furthermore, glucosamine had no adverse effect on cardiac
function for the duration of these experiments (Table 1).
While Luo et al., reported that glucosamine stimulated fatty
acid oxidation in cultured adipocytes [19], their studies focused on
treatment with high glucosamine concentrations (10 mM) over
fairly long time period (i.e. 24 hrs). In contrast, here we show in
the heart that as little as 0.05 mM glucosamine altered substrate
regulation in less than 1 hour with a maximal response at 0.1 mM
glucosamine. In adipocytes the glucosamine-induced increase in
fatty acid oxidation appeared to be mediated via an O-GlcNAc
dependent increase in AMPK activity leading to increased ACC
Figure 4. A) AMPK and B) ACC phosphorylation in the heart after 60 min perfusion with 0.1 mM glucosamine. 0 mM (n=4), 0.1 mM
(n=5).
doi:10.1371/journal.pone.0018417.g004
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regulating energy metabolism in the heart [39,40], in contrast to
adipocytes [19], we found that 0.1 mM glucosamine had no effect
on either AMPK or ACC phosphorylation, which could account
for the increase in fatty acid oxidation (Figure 4). Higher
concentrations of glucosamine had no effect of AMPK phosphor-
ylation, but at 5 and 10 mM we found significantly decreased
ACC phosphorylation (data not shown); however, this would
typically be associated with decreased rather than increased fatty
acid oxidation.
Another potential mechanism for regulating cardiac fatty acid
metabolism is via plasma membrane levels of fatty acid transporter
proteins such as FAT/CD36 [41], which is responsible for ,50–
80% of the fatty acid uptake in the heart [31,32]. Similar to the
glucose transporter GLUT4, FAT/CD36 translocates from
intracellular storage compartments to plasma membrane in
response to stimuli such as insulin or increased cardiac work,
thereby facilitating increased fatty acid oxidation [42,43].
Therefore, we examined FAT/CD36 protein levels in plasma
membrane preparations and found that they increased in a dose
dependent manner with glucosamine treatment (Figures 5A, B).
Preliminary studies also indicated that FAT/CD36 appears to be a
target for O-GlcNAc modification and this was supported by the
fact that OGT, which catalyzes the attachment of O-GlcNAc co-
immunoprecipitated with FAT/CD36 (Figure 5C). Thus, the
glucosamine-induced increase in palmitate oxidation may be due,
at least in part, to increased plasma membrane levels of FAT/
CD36 possibly mediated by increased O-GlcNAc modification of
FAT/CD36. While we did not measure rates of fatty acid
transport across the plasma membrane, previous studies have
demonstrated a close relationship between membrane levels of
FAT/CD36 and rates of fatty acid transport [44]. In the future it
will be important to determine whether acute pharmacological
increases in overall tissue O-GlcNAc levels also lead to increased
O-GlcNAcylation of FAT/CD36 and demonstrate that there is a
relationship between increased FAT/CD36 O-GlcNAc levels and
increased rates of fatty acid transport.
Increased HBP flux has been reported to induce insulin
resistance in muscle, which could also lead to an increase in fatty
acid oxidation. While we cannot rule out the possibility of
decreased insulin sensitivity in this study, the fact that we observed
no effect of glucosamine on glycolytic flux or glucose oxidation,
suggests that this was not a contributing factor to the increase in
fatty acid oxidation. Interestingly, the shift in cardiac metabolism,
seen here with glucosamine, namely increased fatty acid oxidation,
with decreased carbohydrate oxidation primarily as a result of
lower lactate oxidation, is very similar to that previously reported
in the diabetic heart perfused under similar conditions [23].
Furthermore, the increase in myocardial fatty acid oxidation seen
with diabetes has been linked to increased fatty acid transport and
plasma membrane FAT/CD36 expression [43]. In diabetes, the
increased sarcolemmal abundance of FAT/CD36 has been shown
to be a result of impaired recycling between intracellular storage
compartments and the sarcolemma [43]. It is relatively well
established that diabetes also increases overall cardiac O-GlcNAc
levels [14,20]; it is possible, therefore, that in the diabetic heart O-
GlcNAcylation of FAT/CD36 may shift the balance towards
sarcolemmal localization of FAT/CD36 possibly by inhibiting
recycling. Clearly future studies are warranted to determine
whether O-GlcNAc levels of FAT/CD36 are indeed increased in
diabetes and if so, whether this is a contributing factor in the
increased levels of sarcolemmal FAT/CD36. For example,
determine whether acute overexpression of O-GlcNAcase, which
has been shown reverse some of the adverse effects of diabetes on
cardiac function [14], would also reduce sarcolemmal FAT/CD36
levels thereby reverse the metabolic dysfunction.
It is noteworthy that while the increase in fatty acid oxidation
was maximal at 0.1 mM, FAT/CD36 levels continued to increase
up to 5–10 mM glucosamine, similar to the increase in O-GlcNAc
levels. The dissociation between increased membrane levels of
FAT/CD36 and fatty acid oxidation is consistent with studies in
skeletal muscle from obese rats where excess fatty acid uptake was
Figure 5. A) Immunoblots of Plasma membrane fraction for
FAT/CD36 following 60 min perfusion with 0, 0.05, 0.1, 1, 5 and
10 mM; pan-cadherin included as a plasma membrane marker
and protein loading control; B) Densitometric analysis of FAT/
CD36 immunoblots normalized to 0 mM glucosamine; P,0.05
vs. 0 mM, one-way ANOVA with Dunnett’s posthoc test; n=2in
each group; C) Immunoprecipitation of FAT/CD36 from whole
tissue and plasma membrane lysates, followed by O-GlcNAc
and OGT immunoblots. Specificity of O-GlcNAc antibody was
confirmed by co-incubation with 10 mM N-acetylglucosamine (GlcNAc).
doi:10.1371/journal.pone.0018417.g005
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This raises the intriguing possibility that the increased O-GlcNAc
levels seen in the heart in response to diabetes could be a
contributing factor to the accumulation of lipid intermediates that
have been implicated in lipotoxicity. It should be noted however,
that we did not assess the effects of glucosamine on triglyceride
levels; nevertheless, these results suggest that further studies are
warranted to elucidate the effects of the HBP and O-GlcNAcyla-
tion on the partitioning of fatty acids between oxidative and non-
oxidative metabolic pathways in the heart.
While these data here are consistent with the notion that the
effects of glucosamine on myocardial substrate utilization are
mediated via increased O-GlcNAc levels a definitive cause and
effect relationship has not been shown. In the first instance it is
possible that an increase in HBP intermediates could influence
carbohydrate and fatty acid oxidation via mechanisms other than
increased O-GlcNAc levels. For example, increased glucosamine-
6-phosphate levels inhibited hexokinase and stimulated glycogen
synthase activity [46]; however, we found no effect of glucosamine
on lactate efflux rates (Fig. 3A), which suggests that glycolysis was
unaffected. Furthermore, the primary impact of glucosamine on
carbohydrate oxidation was at the level of lactate and pyruvate
oxidation, also supporting the notion that in these experiments
glucosamine had no direct effect on glucose metabolism.
A more definitive approach to demonstrate that OGT is the
primary mediator of the effects of glucosamine would to be to
show that its effects were blocked by pharmacological inhibition of
OGT. Recently novel and potent OGT inhibitors have been
described [47], and their effectiveness in decreasing O-GlcNAc
levels in isolated neonatal cardiomyocytes has been reported [48];
however, in the intact heart 5 mM of one such inhibitor, TT04,
resulted in a marked decline in cardiac function (Chatham,
unpublished data). In the future, studies utilizing the recently
described cardiac specific OGT KO mouse [49] could also
provide valuable insights into the role of O-GlcNAc in the
regulation of cardiac metabolism. However it is of note that in
isolated cardiomyocytes increasing OGT expression typically
mimics the acute effects of glucosamine treatment [50,51], which
is also consistent with concept that that the primary mechanism for
mediating the short-term effects of glucosamine is via an increase
in flux through OGT. An alternative approach that is commonly
used to increase O-GlcNAc levels independent of the HBP is to
inhibit O-GlcNAcase; however, earlier studies were limited due to
relatively low specificity of available inhibitors. Recently, new
highly specific inhibitors have been described [52] and when more
widely available would also be valuable tools for elucidating the
mechanisms by which protein O-GlcNAcylation influences
metabolic regulation.
Our current understanding of cardiac metabolic regulation is
primarily based on substrate availability and the effects of
hormones, particularly insulin, on phosphorylation of key
regulatory proteins including IRS1/2 and AMPK. Increased O-
GlcNAcylation has been implicated in the development of insulin
resistance increasing adipocyte lipid metabolism by direct
modification of IRS1 [53] and AMPK [19] respectively; however,
such results have been under conditions of sustained increases in
HBP flux and O-GlcNAcylation. Here we show for the first time
that glucosamine acutely increases cardiac fatty acid oxidation at
relatively low concentrations, and this was associated by an
increase in overall O-GlcNAc levels. Furthermore, there was also a
dose dependent, glucosamine-induced increase in plasma mem-
brane levels of FAT/CD36 as well as data suggesting that FAT/
CD36 is a potential target for O-GlcNAcylation. Clearly further
studies are needed to elucidate the specific mechanism(s)
associated with the effects of glucosamine on cardiac metabolism;
nevertheless, these data raise the intriguing possibility that the
HBP and O-GlcNAc turnover represent a novel, glucose
dependent mechanism for the acute regulation of cardiac
metabolism. Since the metabolic shift seen with glucosamine is
similar to that seen with diabetes and given that diabetes leads to
chronically elevated O-GlcNAc levels, this may also represent
another mechanism contributing to the metabolic inflexibility that
is characteristic of the effects of diabetes on the heart.
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